NASDAQ · DNTH
Dianthus Therapeutics, Inc.
$82.70+$0.39 (+0.47%)
Dianthus Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.84% below the high.
Loading market information…
NASDAQ · VERA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Vera Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 45.53% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Vera Therapeutics, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$1.61. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Vera Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q4 2024 | Feb 26, 2025 | -$0.72+13.25% vs estimate | $0.00 |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.85-23.19% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 9 contributors · Median target $84.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$82.70+$0.39 (+0.47%)
Dianthus Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.84% below the high.
$31.97+$0.52 (+1.65%)
Arcutis Biotherapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.99% below the high.
$16.49+$0.97 (+6.25%)
Biohaven Ltd.’s quoted price sits in the upper half of its reported 52-week range, 11.2% below the high.
$48.64-$1.86 (-3.68%)
AnaptysBio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.78% below the high.
$12.57+$0.26 (+2.11%)
MoonLake Immunotherapeutics’s quoted price sits in the lower half of its reported 52-week range, 46.03% below the high.
$6.89-$0.24 (-3.37%)
Alumis Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.02% below the high.
$12.13-$0.13 (-1.06%)
Pharming Group N.V.’s quoted price sits in the lower half of its reported 52-week range, 43.16% below the high.
$3.99+$0.03 (+0.76%)
Aclaris Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.55% below the high.
